Evommune (NYSE: EVMN) details Q1 2026 loss, cash runway and Phase 2b catalysts
Rhea-AI Filing Summary
Evommune, Inc. reported first-quarter 2026 results and detailed progress across its chronic inflammation pipeline. Cash, cash equivalents and investments were $307.0 million as of March 31, 2026, up from $216.7 million at year-end 2025, supporting an expected cash runway through 2028.
The company reported no revenue in Q1 2026 versus $3.0 million a year earlier, driven by lower collaboration revenue, and a net loss of $21.7 million, compared with $14.6 million in Q1 2025, as R&D and G&A spending increased.
Evommune highlighted late-stage pipeline catalysts: Phase 2b top-line data for EVO756 in chronic spontaneous urticaria is expected in June 2026 and in atopic dermatitis in the third quarter of 2026, with a Phase 2b migraine prophylaxis trial planned for mid-2026. For EVO301, positive Phase 2a proof-of-concept data in atopic dermatitis support a larger Phase 2b trial using a new subcutaneous formulation planned to start in mid-2027.
Positive
- None.
Negative
- None.
Insights
Evommune strengthens balance sheet while lining up multiple Phase 2b readouts.
Evommune ended Q1 2026 with $307.0 million in cash, cash equivalents and investments, a sizable increase from $216.7 million at year-end 2025. This reflects recent financings and provides runway the company expects will last through 2028, supporting several mid-stage programs.
Operationally, quarterly revenue fell to zero from $3.0 million a year earlier as collaboration revenue rolled off, while net loss widened to $21.7 million with higher R&D and G&A spending. The pipeline update centers on EVO756, with Phase 2b data in chronic spontaneous urticaria due in June 2026 and atopic dermatitis in the third quarter of 2026, plus a migraine prophylaxis study planned for mid-2026.
EVO301 showed positive Phase 2a proof-of-concept data in atopic dermatitis and is being advanced toward a subcutaneous Phase 2b trial targeted for mid-2027. Overall, the filing outlines a catalyst-rich period over 2026–2027 backed by a reinforced balance sheet, but without yet providing pivotal-phase or registrational data that would clearly change the risk profile.
8-K Event Classification
Key Figures
Key Terms
chronic spontaneous urticaria medical
atopic dermatitis medical
Phase 2b medical
proof-of-concept medical
IL-18 binding protein medical
MRGPRX2 medical
Earnings Snapshot
The company stated it expects its cash position to support operations through 2028.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the first quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly stated in any such filing.
Item 7.01 Regulation FD Disclosure.
On May 7, 2026, the Company updated its corporate presentation to reflect certain business updates. The presentation is available in the “Investors & Media” section of the Company's website at ir.evommune.com, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The Company's website and any information contained on the Company's website are not incorporated by reference into this Current Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated May 7, 2026 |
99.2 |
|
Evommune, Inc. Presentation, dated May 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Evommune, Inc. |
|
|
|
|
|
Date: May 7, 2026 |
|
By: |
/s/ Luis Peña |
|
|
|
Luis Peña |
|
|
|
President and Chief Executive Officer |
2
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials
‑ Phase 2b clinical trial evaluating a subcutaneous formulation of EVO301 in AD planned, following positive proof-of-concept (POC) data reported in February 2026
‑ Plans to initiate a Phase 2b dose-ranging clinical trial of EVO756 in migraine prophylaxis in mid-2026
PALO ALTO, Calif. & NEW YORK, May 7, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
“We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for EVO756 in CSU in June and in AD in the third quarter of 2026. We also expect to initiate a Phase 2b clinical trial in a third indication, migraine prophylaxis, in mid-2026, where we believe the biology and opportunity are both very compelling. For EVO301, we recently reported positive Phase 2a proof-of-concept data in AD and look forward to presenting more data from that trial at an upcoming medical meeting,” said Luis Peña, President and Chief Executive Officer at Evommune. “With a strong cash position expected to support our operations through 2028, we believe we are well positioned to execute on key milestones and further advance our pipeline of therapies addressing inflammatory diseases where the biology is strong, the patient need is clear, and the path to development is well defined.”
Business Highlights, Recent Developments and Upcoming Milestones
EVO756 – Oral MRGPRX2 Antagonist Program
Potential first and best-in-class, potent and highly selective small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on both mast cells and peripheral sensory neurons. This dual expression allows MRGPRX2 to uniquely modulate the neurogenic inflammation feedback loop between nerves and immune cells that drive chronic inflammation.
EVO301 – Injectable IL-18 Binding Protein Fusion Protein
Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies.
“We are excited to present a robust set of preclinical and translational findings at upcoming scientific conferences,” said Dr. Jeegar Patel, Chief Scientific Officer at Evommune. “We continue to build a compelling body of evidence supporting shared disease biology across CIndU and CSU, while further elucidating the role and expression of the MRGPRX2 receptor in AD. Importantly, our migraine-focused research expands this understanding into the neuroinflammatory setting, demonstrating MRGPRX2’s involvement in both meningeal mast cells and trigeminal neurons. Collectively, these findings reinforce our conviction in MRGPRX2 as a highly differentiated and potentially broad therapeutic target, continuing to build momentum as we look ahead to upcoming top-line Phase 2b data in CSU next month.”
First Quarter 2026 Financial Results
About Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway through 2028; and continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Evommune, Inc. |
|
||||||||
Unaudited Condensed Consolidated Statements of Operations |
|
||||||||
(in thousands, except share and per share data) |
|
||||||||
|
|
|
|
|
|
|
|
||
|
Three Months Ended |
|
|||||||
|
March 31, |
|
|||||||
|
2026 |
|
|
2025 |
|
||||
Revenues: |
|
|
|
|
|
|
|
||
License revenue |
$ |
|
— |
|
|
$ |
|
3,000 |
|
Operating expenses: |
|
|
|
|
|
|
|
||
Research and development |
|
|
17,319 |
|
|
|
|
14,362 |
|
General and administrative |
|
|
6,635 |
|
|
|
|
3,670 |
|
Total operating expenses |
|
|
23,954 |
|
|
|
|
18,032 |
|
Loss from operations |
|
|
(23,954 |
) |
|
|
|
(15,032 |
) |
Total other income, net |
|
|
2,280 |
|
|
|
|
475 |
|
Net loss |
|
|
(21,674 |
) |
|
|
|
(14,557 |
) |
Basic and diluted net loss per share of common stock |
$ |
|
(0.64 |
) |
|
$ |
|
(9.48 |
) |
Weighted average basic and diluted shares of common stock outstanding |
|
|
33,670,148 |
|
|
|
|
1,534,965 |
|
Evommune, Inc. |
|
|||||||||
Unaudited Condensed Consolidated Balance Sheets |
|
|||||||||
(in thousands) |
|
|||||||||
|
|
|
|
|
|
|
|
|
||
|
|
March 31, |
|
|
December 31, |
|
||||
|
|
2026 |
|
|
2025 |
|
||||
Cash, cash equivalents and short-term investments |
|
$ |
|
211,464 |
|
|
$ |
|
149,200 |
|
Other current assets |
|
|
|
4,391 |
|
|
|
|
4,278 |
|
Long-term investments |
|
|
|
95,548 |
|
|
|
|
67,489 |
|
Other non-current assets |
|
|
|
11,052 |
|
|
|
|
3,979 |
|
Total assets |
|
$ |
|
322,455 |
|
|
$ |
|
224,946 |
|
|
|
|
|
|
|
|
|
|
||
Current liabilities |
|
$ |
|
10,603 |
|
|
$ |
|
17,909 |
|
Other non-current liabilities |
|
|
|
7,297 |
|
|
|
|
1,471 |
|
Total liabilities |
|
|
|
17,900 |
|
|
|
|
19,380 |
|
Total stockholders’ equity |
|
|
|
304,555 |
|
|
|
|
205,566 |
|
Total liabilities and stockholders’ equity |
|
$ |
|
322,455 |
|
|
$ |
|
224,946 |
|
Contacts:
Media:
Paul Laland
Paul.laland@evommune.com
Investors:
Sarah McCabe
investors@evommune.com
May 2026 © Evommune, Inc. Corporate Presentation
Disclaimers © Evommune, Inc. This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding the potential benefits, clinical activity and tolerability of our product candidates; our expectations with regard to the results of our clinical trials, preclinical studies and research and development programs, including the the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of our product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway; and continued advancement of our portfolio. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. These and other risks are described more fully in our Annual Report on Form 10-K for the year ended December 31, 2025 and our other filings with the Securities and Exchange Commission (the “SEC”) and our other documents subsequently filed with or furnished to the SEC. All forward-looking statements represent our views as of the date of this presentation. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except to the extent required by law, we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. This presentation also contains estimates made by independent parties relating to industry market size and other data. These estimates involve a number of assumptions and limitations, and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracy or completeness of such information and we do not take any responsibility with the accuracy or completeness of such information. The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.
Evommune (EVMN) is Addressing Chronic Inflammation, a Global Healthcare Crisis 5 Substantial Burden on the Healthcare System Annual direct cost of at least $90B2 Existing Treatment Options Have Critical Limitations Current therapies fail to deliver efficacy and safety suitable for the majority of patients Chronic Inflammation Destroys Lives Contributes to 3 out of 5 deaths worldwide1 Experienced Team Distinct Mechanisms Portfolio Approach Evommune is Delivering Next Generation Therapies Footnotes: https://www.ncbi.nlm.nih.gov/books/NBK493173/ Wylezinski LS, et al. J Clin Med. 2019;8:493 © Evommune, Inc.
5v Our Mission-Driven Approach to Treating Immune-Mediated Diseases © Evommune, Inc. Two Phase 2 Programs with Novel Approaches to Targeting Heterogeneous Diseases EVO756: Oral Therapy Targeting Mast Cells and Sensory Neurons EVO301: IL-18 Blockade for Multi-Pathway Immunomodulation Address critical gaps in care… Expansive Portfolio of Preclinical Programs Sensory Neuron Mast Cell MRGPRX2 Nerves Mast Cells Novel Biologic Using the Fully Human IL-18 Binding Protein Adaptive (Th2) Inflammation Innate Inflammation …Strategically select mechanisms with strong probability of success… … Steady cadence of new programs entering the clinic
Our Inflammation Portfolio © Evommune, Inc. Program / Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone EVO756 MRGPRX2 Chronic Spontaneous Urticaria Phase 2b Data (June 2026) Atopic Dermatitis Phase 2b Data (Q3 2026) Migraine Phase 2b Trial Initiation (mid-2026); Topline Data (2027) Other Indications Phase 2 Trial Initiation (2027) EVO301 IL-18 Atopic Dermatitis Positive Phase 2a POC: Full Data to be presented at an upcoming medical meeting Phase 2b Trial planning underway Ulcerative Colitis Phase 2 Trial planning underway Other Indications Phase 2 Trial planning underway Advancing Multiple Preclinical Programs Toward Clinical Proof-of-Concept
EVO756: Oral MRGPRX2 Antagonist Targeted Approach to Controlling Mast Cell Mediated Diseases and Neuroinflammation © Evommune, Inc.
EVO756: Broad Spectrum Oral Anti-Inflammatory Potential MRGPRX2 Expressed on Both Mast Cells and Sensory Neurons Potent and highly selective small molecule Oral convenience could drive adoption across multiple indications Anticipate favorable safety and tolerability profile Potential First-Line Oral Across Several Specialties Sensory Neuron Mast Cell MRGPRX2 Nerves Mast Cells Mast Cells and Sensory Neurons Are Found in Close Proximity MRGPRX2 © Evommune, Inc.
Mast Cell MRGPRX2 Ligands Tissue Damage Sensory Neuron Vasodilation, Extravasation Immune Recruitment / Activation Sensory Neuron Activation Mast Cell Degranulation Itch / Pain / Cough Tissue Pathophysiology Clinical Manifestations Inflammatory Infiltrates Increased Mast Cell Numbers Innate Immunity Adaptive Immunity Tissue Remodeling Vascular Leak Neuronal Sensitivity Chronic Inflammation Erythema Hives Barrier Dysfunction Airflow Limitation Edema Angioedema Sensitivity to Chemicals / Foods MRGPRX2 Neuropeptides Mast Cell Mediators Inflammatory Mediators MRGPRX2 in Mast Cell Activation and Neuroinflammation © Evommune, Inc.
EVO756 Development Roadmap: Demonstrate Proof-of-Concept and Expand into Additional Indications Initially pursue inflammatory diseases with: Underserved patient population Economic viability Well-defined clinical and regulatory development pathway Cutaneous Neurological Respiratory Other EVO756 Development Strategy Footnotes: Proof-of-concept based on skin challenge test in healthy volunteers Proof-of-concept supported by positive clinical data for PACAP (MRGPRX2 ligand) inhibition in migraine prophylaxis (Lundbeck) Migraine2 Asthma Chronic Urticarias Atopic Dermatitis1 Irritable Bowel Syndrome Interstitial Cystitis © Evommune, Inc.
10 EVO756 Clinical Data © Evommune, Inc. Dual Mechanism Modulates Both Mast Cells and Peripheral Sensory Neurons
EVO756: Encouraging Results in Two Clinical Trials Support Initial Development in CSU and AD © Evommune, Inc. CIndU = Chronic inducible urticaria; CSU = Chronic spontaneous urticaria; AD = Atopic dermatitis EVO756 Clinical Development Summary Trial Phase 1 Proof-of-Concept Phase 2 Phase 2b Phase 2b N 132 30 ~160 ~120 Indication Healthy Volunteers CIndU CSU AD Key Takeaways Well-tolerated across all doses Clear target engagement in skin challenge Concentration dose proportional and linear Well-tolerated across all doses Complete responses as early as week 1 POC achieved after just 4 weeks of dosing Topline Data Expected Q2 2026 Topline Data Expected Q3 2026
PART A: SAD Dosing N = 55 (41 active / 14 placebo) EVO756: Phase 1 Proof-of-Concept Trial Design and Summary Inclusion of Skin Challenge in MAD Portion Allowed Early PD Assessment and Trial Showed Positive Pharmacokinetics and Pharmacodynamics © Evommune, Inc. ECG = Electrocardiogram Cohort A1 1 mg Cohort A5 100 mg Cohort A4 30 mg Cohort A3 10 mg Cohort A2 3 mg Cohort A6 240 mg Cohort A7 500 mg Cohort B1 10 mg BID Cohort B3 100 mg BID Cohort B2 30 mg BID Cohort B4 240 mg BID Cohort B5 500 mg QD PART B: MAD Dosing N = 77 (58 active / 19 placebo) Included Skin Challenge at All Doses Pharmacokinetics Pharmacodynamics – Icatibant Skin Challenge Test Safety Concentration dose proportional and linear Half-life ranges from 8 - 12 hours Tmax: 1 - 4 hours Support QD and BID dosing Clear target engagement Dose dependent activity All doses associated with response Well-tolerated across all doses No severe or serious adverse events No clinically significant abnormal lab values No clinically significant ECG abnormalities
EVO756: Phase 2 Trial in Chronic Inducible Urticaria (CIndU) Data © Evommune, Inc.
5v Phase 2 Chronic Inducible Urticaria (CIndU) Trial Design © Evommune, Inc. SD = symptomatic dermographism; TEAE = Treatment Emergent Adverse Events; BL = Baseline. Trial identifier: NCT06603220 Follow-up Screening Enrollment End of Trial BL W6 EVO756, 300 mg QD EVO756, 50 mg BID W4 Patient Population Symptomatic dermographism, Total FricTest Score ≥2 Primary Endpoint Safety as assessed by incidence of TEAEs Efficacy Measures Complete response, change from baseline in provocation test Total FricTest Score Change from baseline in Pruritus-NRS at provocation site Biomarker Data Patient subtyping (e.g., IgE high and low) Pharmacodynamics and disease severity Adults with Chronic Inducible Urticaria (N = 30) Open Label, Within-Patient Controlled Trial (All with SD)
Both Doses Demonstrated Robust Clinical Activity At Just 4 Weeks, 70% ≥1 Pt Improvement, 41% ≥2 Pt Improvement, 30% Complete Response Rate © Evommune, Inc. Evommune clinical data; 1. Four of the complete responders were IgE high; 2. 75% (n=6) of those who did not achieve a decrease in FricTest score demonstrated a decrease in pruritus-NRS, evidencing the impact of EVO756 on itch at this early time point, even in the absence of FricTest response Standardized provocation test 4 calibrated tines FricTest FricTest Response at Week 4 300 mg QD 50 mg BID All N (efficacy) 10 17 27 Complete Response 3 (30%) 5 (29%) 8 (30%)1 Partial Response ≥ 2-point Decrease 1 (10%) 2 (12%) 3 (11%) 1-point Decrease 2 (20%) 6 (35%) 8 (30%) No Response 4 (40%) 4 (24%) 8 (30%)2
EVO756 Potential for Increased Response with Longer Dosing Omalizumab and Barzolvolimab Activity Continued to Improve Over Time © Evommune, Inc. Week Mean FricTest Score (0-4) 0 4 10 12 EVO756 50mg BID* EVO756 300mg QD Omalizumab 150 mg Q4W Omalizumab 300 mg Q4W Barzolvolimab 150 mg Q4W Barzolvolimab 300 mg Q8W For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and study characteristics, and caution should be exercised when comparing across trials. Sources: Evommune clinical data (observed), competitor data from Maurer et al. (2017), Maurer et al., ACAAI (2024) Observations Comparable baseline disease severity shown between EVO756 and other SD trials At week 4, 300 mg QD patients (N=10) saw a 1.4 point reduction and 50 mg BID patients (N=17) saw a 1.5 point reduction Clinical response may continue to improve past week 4 similar to other agents Clinical Improvements Over Time
5v Safety Summary Well Tolerated Across All Evaluated Dosing Levels © Evommune, Inc. Evommune clinical data; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 1. The two subjects in the 300 mg QD cohort with AEs of increased ALT and AST had asymptomatic transaminase elevations that were greater than ten times the upper limit of normal at four weeks, which were not present at baseline, week 1 or week 2 and later returned to baseline. Other liver tests, including bilirubin and alkaline phosphatase were within normal limits. Both of these subjects had confounding factors that may have contributed to these elevations. 300 mg QD N = 11 50 mg BID N = 19 ALT/AST Increased 2 (18%)1 – Gastroenteritis 1 (9%) 1 (5%) Pruritus 1 (9%) 1 (5%) Summary of Treatment Emergent Adverse Events Occurring in >1 Patient EVO756 was Generally Well Tolerated No serious adverse events No treatment discontinuations due to adverse events
EVO756: Pharmacokinetic (PK) Data and Molecular Properties © Evommune, Inc.
Pharmacokinetic Modeling Based on Clinical Data to Date IC90 Coverage Across All Dose Levels Supports Potential QD and BID Dosing Regimens Footnotes: IC90 Primary Mast Cells = 180 ng/mL © Evommune, Inc. Day 10 Median Concentrations Relative Plasma EVO756 Concentrations (ng/mL) Time (hours) IC90 Multiple of IC90 at Trough 5.1x 2.1x 1.2x
EVO756 Phase 2b Dose Selection Rationale Understanding of Dose Response Evolved During CIndU Study, Guiding Phase 2b Trial Doses © Evommune, Inc. Active across all icatibant doses 10 μg/mL icatibant dose is most relevant comparison based on patient biopsies Suggests potential activity as low as 10 mg BID PK/PD Modeling Refined model to predict IC90 coverage at trough Suggested complete coverage as low as 25 mg BID High tissue penetration in human skin (~70%) Strong activity in 300 mg QD dose provided confidence to explore lower doses 50 mg BID dose had similar activity EVO756 Phase 2 CIndU Results HV Icatibant Skin Challenge Selection of Phase 2b Doses Potential for large therapeutic window; driving approach to dose-ranging trials
EVO756: Phase 2b Trial in Chronic Spontaneous Urticaria (CSU) © Evommune, Inc.
EVO756 Blocks MRGPRX2 & IgE Mast Cell Degranulation Suggests benefit of MRGPRX2 inhibition for all CSU endotypes In Mast Cells, MRGPRX2 and FcER Pathways Converge Dual Activation of MRGPRX2 and IgE Potently Drives Degranulation, and EVO756 Blocks this Effect SP – Substance P. Mast cell degranulation assayed via CD107a expression © Evommune, Inc. MRGPRX2 FceR MRGPRX2 Ligands IgE Degranulation Ca2+ Influx PLC Activation Unstimulated Low Concentration Single Agonist MRGPRX2 & FcER Agonists Together EVO756 Pre-treatment + MRGPRX2 & FcER Agonists
Strong Evidence of Overlap between CIndU and CSU Pathogenesis Lesional (L) Non-lesional (NL) ISF collected using microneedle device Chronic Spontaneous Urticaria (CSU) Chronic Inducible Urticaria (CIndU) Baseline Cold provocation 15 minutes & 4 hours ISF collected using microneedle device Interstitial Fluid (ISF) Collection Mass Spectrometry Results Inflammation Panel Increased Mast Cell Activation in CSU and CIndU ISF MRGPRX2 Ligands Upregulated in CSU and CIndU Shared Set of Top 10 Secreted Proteins Enriched in CSU and CIndU ISF CSU CIndU CSU CIndU CSU CIndU NL = non-lesional, L = lesional. 0 and 15 are time in minutes © Evommune, Inc.
Relationship Between CIndU Efficacy and Impact on CSU Phase 2 EVO756 Results in CIndU Provide Early Support for Potential CSU Clinical Profile © Evommune, Inc. Direct comparisons cannot be made in the absence of head-to-head trials because of differences in trial design, patient population and other factors. Data is presented for information only and does not account for difference in enrollment populations or other cross-trial variabilities MOA Cell Target Drug CIndU CSU IgE Mast Cells Basophils Eosinophils omalizumab KIT Mast Cells Hematopoietic Stem Cells Germ Cells Melanocytes barzolvolimab BTK Mast Cells B Cells Basophils Myeloid Cells remibrutinib IL-4 / IL-13 Th2 Cells Epithelial Cells Macrophages dupilumab Correlation Between CIndU Success and CSU Benefit
Phase 2b Dose-Ranging Trial in CSU Top-Line Data Expected Q2 2026 © Evommune, Inc. UAS7 = Urticaria Activity Score over 7 days; ISS7 = Itch Severity Score component of UAS7; HSS7 = Hives Severity Score component of UAS7; AAS7 = Angioedema Activity Score; BL = Baseline; Mod-to-Sev = Moderate-to-Severe. Trial identifier: NCT06873516 Primary Endpoint Mean change from baseline in UAS7 at Week 12 Key Secondary Endpoints UAS7 ≤ 6 and UAS7 = 0 Change in ISS7 Change in HSS7 Change in AAS7 Exploratory Biomarkers Patient subtyping (e.g., IgE high and low) Pharmacodynamics and disease severity Prior exposure to omalizumab allowed 5v BL W14 Adults with Mod-to-Sev CSU, Refractory to H1 Antihistamines (N = 160) Randomized, Double-Blind, Placebo-Controlled Trial Follow-up Screening Enrollment End of Trial W12 EVO756, Dose 1 EVO756, Dose 2 EVO756, Dose 3 Placebo
EVO756: Potential to Address an Urticaria Market With Significant Therapeutic Opportunity Anti-IgE Therapy Blocks Mast Cell Activation Anti-KIT Depletes Mast Cells Anti IL-4 / IL-13 Blocks T2 Cytokines MRGPRX2 Antagonists Blocks Mast Cell Activation Modulates Neuro-inflammation KIT Inhibitors Depletes Mast Cells BTK Inhibitors, JAK Inhibitors Inhibits Signaling Anti-Histamines Blocks Mediators Oral Injectables Highly Targeted to Mast Cells Broad Effect on Immune Cells © Evommune, Inc. Selectivity Convenience Therapeutic Approaches in CSU
Estimated CSU Prevalence1 Eligible CSU Patients2 Untreated by Advanced Therapies3 CSU is an Underserved Market with Limited Treatment Options Footnotes: In the US; Maurer et al. (2011) In the US; “Eligible” defined as CSU patients with incomplete response to OTC H1-antihistamines and eligible for targeted therapy Approximately 50K patients currently treated with a biologic Potential for differentiated clinical activity profile Oral dosing Well tolerated EVO756 Profile Potentially Amenable to First Line Treatment ~450K ~3M ~400K EVO756 Market Opportunity in Patients R/R to Antihistamines, Majority Currently Off Treatment © Evommune, Inc.
EVO756 in Atopic Dermatitis (AD) © Evommune, Inc.
MRGPRX2 is Only Dual MOA: Targeting Inflammatory Lesions and Neuroinflammation Strong Scientific Rationale for EVO756 in AD Expect Benefit on Mast Cell and Neuroinflammation Aspects of AD © Evommune, Inc. Pathway activation in disease and preclinical evidence of Mrgprb2/X2 involvement Strong translational validation Broad therapeutic potential MOA likely effective across patient endotypes Direct effect on sensory neurons Rapid impact on itch Dual mechanism impacting key inflammatory pathways Mast cell and neuroinflammatory disease Sensory Neuron Mast Cell MRGPRX2 Nerves Mast Cells
CytoReason Collaboration: in silico AD Model Identifies and Validates Opportunities Beyond IL-4/IL-13 © Evommune, Inc. MRGPRX2 Signature Generation Computational Engine Clinical Anchoring in silico AD Model From RNAseq of in vitro human mast cells activated with MRGPRX2 ligands with/without EVO756 Integration of MRGPRX2 signature, 24 RNAseq datasets, >2,000 of human skin biopsies Model calibration against EASI scores and Dupilumab response data Acts as digital twin by integrating high-dimensional molecular data with real world clinical endpoints In collaboration with
Predictive Modeling Reveals MRGPRX2 as a Core to AD Pathophysiology © Evommune, Inc. Magenta = Th2 signatures; Teal = Itch / Neuroinflammation signatures, Green = Th22 signatures, Blue = Th17 signatures Broad reach may enable EVO756 to potentially outperform IL-4/-13–restricted approaches In collaboration with
MRGPRX2 Captures Core IL-4/-13 Biology and Broader Disease Drivers © Evommune, Inc. Shared Biology MRGPRX2 and IL-4/-13 signatures capture both Th2 inflammation and neuroinflammation Differentiated Coverage MRGPRX2 uniquely captures “white space” biology, including cellular proliferation and barrier pathways MRGPRX2 molecular signature remains expressed in non-responders to IL-4/-13 standard of care Implications Complementary—not redundant—mechanism Potential to expand efficacy beyond current standard of care In collaboration with
Phase 2b Dose-Ranging Trial in AD Top-Line Data Expected Q3 2026 © Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; Pruritus-NRS = Pruritus Numerical Rating Scale; BSA = Body Surface Area; BL = Baseline. Trial identifier: NCT07150845 Primary Endpoint Percent change from EASI at Week 12 Key Secondary Endpoints EASI-50, EASI-75, and EASI-90 Change in vIGA Change in Pruritus-NRS Proportion of patients achieving ≥4 point reduction in Pruritus-NRS Change in BSA affected Exploratory Biomarkers Patient subtyping Pharmacodynamics & disease severity 5v BL W14 Adults with Moderate-to-Severe Atopic Dermatitis (N = 120) Randomized, Double-Blind, Placebo-Controlled Trial Follow-up Screening Enrollment End of Trial W12 EVO756, Dose 1 EVO756, Dose 2 EVO756, Dose 3 Placebo
Estimated Adult AD Prevalence1 Patients with Moderate-to-Severe Disease Patients Eligible for Targeted Therapy AD is an Underserved Market Lacking a First-Line Oral Option Current Therapies Fail to Deliver Both Lesion Control and Itch Relief, While Also Being Well-Tolerated Footnotes: In the US; Atopic dermatitis impacts >100M adults and more than 102M children worldwide. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. British Journal of Dermatology 2023 Dec 20;190(1):55-61. Potential for differentiated clinical activity profile on lesions and itch Oral dosing Well tolerated EVO756 Profile Potentially Amenable to First Line Treatment ~6M-8M ~16M EVO756 Market Opportunity Across Patient Populations within AD ~1.4M-1.8M © Evommune, Inc.
EVO756 in Migraine © Evommune, Inc.
MRGPRX2: Positioned to Address Neuronal and Mast Cell Drivers of Migraine © Evommune, Inc. Source: Evommune internal data (trigeminal neurons; in situ hybridization on human tissue samples), PMID40712576 (meningeal mast cells) Expression Confirmed in Disease-Relevant Tissues MRGPRX2 nuclei Trigeminal Ganglia Meningeal Mast Cells MRGPRX2 Mediates Neuropeptide Signaling Associated with Migraine (PACAP, VIP, Substance P) Meningeal Mast Cells: Perivascular cells in the dura responsive to PACAP, VIP, and Substance P Trigeminal Neurons: Primary sensory neurons mediating migraine pain Meninges Trigeminal Afferents
Inhibition of MRGPRX2 Ligand PACAP Achieves CGRP-Like Efficacy in Migraine Prophylaxis © Evommune, Inc. Note: Lundbeck’s bocunebart is a humanized mAb that neutralizes PACAP. Results above from Phase 2 a study in migraine prophylaxis (HOPE; N=237; single IV administration of bocunebart in patients that were a mix of episodic and chronic migraineurs). Source: Clinicaltrials.gov NCT05133323. Direct comparisons cannot be made in the absence of head-to-head trials because of differences in trial design, patient population and other factors. Lundbeck’s Bocunebart Reduced Monthly Migraine Days by ~2 Second Neuropeptide Axis Validated in Migraine Prevention PACAP likely acts through MRGPRX2 as a key neuropeptide trigger of migraine attacks Antibody blockade reduced migraine frequency in controlled clinical study Effect size falls within range observed for approved CGRP therapies Magnitude of benefit consistent with marketed CGRP inhibitors Mean Change in Monthly Migraine Days Bocunebart (IV) Placebo
3 Neuropeptides that Trigger Migraine Signal Through MRGPRX2 Neuropeptide Preclinical Evidence Induced Headache in Humans Clinical Validation PACAP VIP TBD Substance P TBD MRGPRX2 Inhibition May Offer Broader Migraine Benefit than Targeting PACAP Alone © Evommune, Inc. Note that PACAP also binds PAC1, VPAC1, VPAC2, but PAC1 inhibition does not show therapeutic benefit in migraine. PACAP VIP Substance P MRGPRX2
Planned Phase 2b Dose-Ranging Trial in Migraine Prophylaxis Initiation Expected Mid-2026 © Evommune, Inc. BL = Baseline; CFB = change from baseline; MMD = monthly migraine days; MHD = monthly headache days; QoL = quality of life BL Adults with Refractory Migraine ≥6 Days/Month (N ≈ 330) Screening Enrollment W12 EVO756, Dose 1 EVO756, Dose 2 Placebo Randomized, Double-Blind, Placebo-Controlled Trial Primary Endpoint Mean CFB in MMD Key Secondary Endpoints ≥50%, ≥75% reduction in MMD CFB in MHDs and MMD CFB in monthly acute migraine medication use Exploratory Endpoints Patient subtyping Changes in biomarkers Change in migraine-specific QoL Exploring daily doses up to100 mg
EVO301: IL-18BP Fusion Protein Long-Acting Serum Albumin-Binding Injectable Therapeutic Fusion Protein Designed to Neutralize IL-18 Signaling © Evommune, Inc.
IL-18 Immune Rebalancing: Modulate Innate and Adaptive Inflammation for Potential Disease Remission © Evommune, Inc. PAMPs: Pathogen-associated molecular patterns; DAMPs: Damage-associated molecular patterns Chronic Inflammation Tissue Pathophysiology Clinical Manifestations Inflammatory Infiltrates Inflammatory Cytokines Autoimmunity Angiogenesis Th1, 2, 17 Differentiation Barrier Dysfunction Infection Tissue Damage Pathogen Clearance IL-18BP Therapeutic Approach Involved in Innate and Adaptive Immune Processes IL-18 producing cells IL-18 responding cells Stromal/mesenchymal IL-18 Epithelial Endothelial CD4 T NK CD8 T Macrophage Dendritic cell Dendritic cell Macrophage Dysbiosis Tissue Injury Infection DAMPs* PAMPs* IL-18R1 IL-18RAP No Response Activation IL-18 IL-18BP Epithelial Barrier
EVO301: Long-Acting IL-18 Neutralizer Designed for Tissue Targeting SAFA and IL-18BP fused via peptide linker for extended neutralization of IL-18 activity © Evommune, Inc. SAFA - Anti-Serum Albumin Fab-Associated. HSA – Human Serum Albumin SAFABODY™ is a trademark of AprilBio Co., Ltd. Free IL-18 IL-18 IL-18 BP SAFA Peptide linker Albumin SAFAbody™ Platform Technology T½ extension: FcRn-mediated recycling of HSA Efficient tissue distribution: Smaller size (MW ~65 kD) and HSA binding IL-18 Binding Protein (IL-18BP) High binding affinity and specificity Native fully human sequence
Biologic Pathway Adaptive Inflammation Innate Inflammation Skin Barrier (IL-22) TH2 TH1 TH17 IL-18 DUPIXENT® EBGLYSS® ADBRY® NEMLUVIO® EVO301 Addresses Limitations of Existing Biologics; Demonstrating Ability to Impact Multiple Drivers of AD, while being Well Tolerated © Evommune, Inc. Green = impacts biological pathway; Red = negative effect. Broader inflammatory signaling of IL-18 can address endotypes not fully captured by Th2-targeted therapies —enabling potential for broader patient coverage and efficacy
EVO301 Phase 2a Proof of Concept Trial Design © Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; BSA = Body Surface Area; BL = Baseline; PBO = Placebo. Trial identifier: NCT06723405 Screening Randomization 2 Active : 1 PBO End of Trial BL W12 W4 Adults with Moderate-to-Severe Atopic Dermatitis (N = 70) Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial AD Population EASI ≥16 vIGA ≥3 BSA ≥10% Primary Endpoint Percent change from EASI at Week 12 (Bayesian) Pharmacokinetics Target Engagement W8 EVO301: 5 mg/kg IV Placebo Dosing day Dosing day W2
EVO301 Achieved the Primary Endpoint Phase 2a Proof-of-Concept Trial in Moderate-to-Severe Atopic Dermatitis Highly statistically significant EASI reductions at weeks 4, 8, and 12 versus placebo 34% and 33% placebo adjusted improvement in EASI at week 8 and 12, respectively 23% of patients achieved IGA 0/1 at week 12 versus 0% placebo Well-tolerated, with no treatment related serious or severe adverse events reported Corresponding reductions in secondary endpoints, as well as key Th2 and non Th2 cytokines Pharmacokinetics (PK) continues to support a Q4 week dosing regimen © Evommune, Inc. Clinical Data Supports Continued Development, with Phase 2b Planning Underway
Disposition, Baseline Demographics and Disease Characteristics © Evommune, Inc. Note: Numbers in parentheses are standard deviations. BMI: body mass index, EASI: Eczema Area and Severity Index, IGA: Investigator’s global assessment, NRS: numeric rating score, BSA: body surface area, SD: standard deviation. Subjects who were early terminations were 1. Lost to follow-up. 2. Lost to follow-up and subject withdrawal Trial well-balanced across cohorts EVO301 Placebo N (treated) 48 22 N (completed) 451 202 Age 30.5 (11.1) 33.1 (11.8) Gender (female, %) 29 (60.4%) 13 (59.1%) Weight (kg) 78.5 (18.7) 76.4 (17.5) BMI (kg/m2) 27.4 (6.0) 28.1 (6.3) EASI 30.0 (11.8) 29.8 (10.5) IGA 3.3 (0.5) 3.5 (0.5) Pruritus-NRS 6.3 (1.5) 6.7 (2.1) % BSA 47.1 (21.2) 49.3 (16.1)
Phase 2a Trial in AD Met Primary Outcome Measure (Bayesian) EASI: Eczema Area and Severity Index, SD: standard deviation, HPD: high posterior density % Change in EASI at Week 12: Protocol Success Criterion Met Statistic EVO301 versus Placebo Success Criterion: Posterior Probability of Difference < -8% 75% Trial Results: Posterior Probability of Difference < -8% 99.8% Posterior Mean Difference -32 95% HPD Interval for Difference in Mean -47, -15 © Evommune, Inc.
Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points EASI: Eczema Area and Severity Index % Change in EASI by Study Visit Visit EVO301 Placebo Placebo-adjusted Change p-value Week 4 -41 -18 -23 <0.01 Week 8 -50 -16 -34 <0.01 Week 12 -55 -22 -33 <0.01 © Evommune, Inc.
Week 2 Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points © Evommune, Inc. Week 0 Week 4 Week 8 Week 12 % Average Change in EASI ↓ Dosed at Weeks 0 and 4 Placebo EVO301 * * % Change in EASI by Study Visit *p<0.01 ↓ % Average change in EASI is LS Mean -22 -18 -16 -22 -30 -41 -50 -55 ↓ *
IL-18 IL-31 IL-13 IL-4 / IL-13 Two Doses of EVO301 Demonstrated Comparable Activity at 12 Weeks to Dose-Optimized Marketed Biologics at 16 Weeks © Evommune, Inc. For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and study characteristics, and caution should be exercised when comparing across trials. Sources: Silverberg et al. (2016), Silverberg et al. (2023), Wollenberg et al. (2020), Ruzicka et al. (2017). Placebo-Adjusted % Improvement from Baseline in EASI Dose-Optimized Products # Doses: 2 8 8 8 8 8 8 3 EVO301 EVO301-AD001 Phase 2a 12 week N = 70 5 mg/kg IV Dupixent® SOLO 1 Phase 3 16 week N=671 600 mg W0 300 mg Q2W Dupixent® SOLO 2 Phase 3 16 week N=708 600 mg W0 300 mg Q2W Ebglyss™ ADVOCATE 1 Phase 3 16 week N=424 500 mg W0, W2 250 mg Q2W Ebglyss™ ADVOCATE 2 Phase 3 16 week N=427 500 mg W0, W2 250 mg Q2W Adbry® ECZTRA 1 Phase 3 16 week N=802 300 mg Q2W Adbry® ECZTRA 2 Phase 3 16 week N=794 300 mg Q2W Nemluvio® Phase 2a 12 week N=264 2 mg/kg QW4
↑ Week 0 ↑ Week 4 Week 8 Week 12 vIGA Response Phase 2a Trial in AD: Early Clinical Signal in vIGA 0/1 Response © Evommune, Inc. vIGA: Validated Investigator’s Global Assessment Visit EVO301 Placebo Week 4 4.2% 0% Week 8 12.5% 0% Week 12 22.9% 0% vIGA Response (≥2-point improvement and a score of 0 or 1) ↑ Dosed at Weeks 0 and 4 Placebo EVO301
Safety Summary Over 12 Week Trial Period EVO301 Was Well Tolerated © Evommune, Inc. No Clinically Significant Lab Abnormalities. No Conjunctivitis Reported (as is Common with Other Biologics in AD) EVO301 Placebo Total N=48 N=22 N=70 Patients with ≥1 Adverse Event (AE) 30 (62.5%) 16 (72.7%) 46 (65.7%) Patients with ≥1 Treatment Related AE 5 (10.4%) 3 (13.6%) 8 (11.4%) Patients with a Related Serious or Severe AE 0 0 0 AEs Leading to Study Discontinuation 0 0 0 AEs > 5% in Either Arm EVO301 Placebo Total Upper respiratory tract infection 10 (20.8%) 4 (18.2%) 14 (20.0%) Atopic dermatitis 10 (20.8%) 9 (40.9%) 19 (27.1%) Headache 8 (16.7%) 3 (13.6%) 11 (15.7%) Nasopharyngitis 4 (8.3%) 0 4 (5.7%) Viral upper respiratory tract infection 3 (6.3%) 2 (9.1%) 5 (7.1%) Dizziness 3 (6.3%) 1 (4.5%) 4 (5.7%) Fatigue 3 (6.3%) 0 3 (4.3%)
EVO301 Subcutaneous Formulation Exposure Consistent with IV © Evommune, Inc. Comparable Nonclinical Serum Exposure Key PK Parameters Parameters 10 mg/kg (N = 3/group) Intravenous (IV) Subcutaneous (SC) Cmax (mg/mL) 343 90 AUC (mg•hr/mL) ~27,000 ~27,000 Tmax (hr) 0.83 72 T1/2 (hr) 101 168 0.1 1.0 10.0 100.0 1,000.0 Time (weeks) Concentration (mg/mL) IC90 (CD4+ T Cells) IV SC
5v Planned EVO301 Phase 2b Dose-Ranging Trial in AD Trial Initiation Expected Mid-2027 © Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; Pruritus-NRS = Pruritus Numerical Rating Scale; BSA = Body Surface Area; BL = Baseline, QoL = Quality of Life Q4W = Every four week dosing, Q2W = Every two week dosing, LD = Loading Dose. Primary Endpoint % CFB in EASI Key Secondary Endpoints EASI-50, EASI-75, and EASI-90 Change in vIGA Change in Pruritus-NRS Proportion of patients achieving ≥4 point reduction in Pruritus-NRS Change in BSA affected Exploratory & Biomarkers QoL Biomarkers Target Engagement BL W16 Adults with Moderate-to-Severe Atopic Dermatitis (N ≈ 180) Randomized, Double-Blind, Placebo-Controlled Trial Screening Enrollment End of Trial W10 EVO301: Dosing Regimen 1 EVO301: Dosing Regimen 2 EVO301: Dosing Regimen 3 Placebo W2 W6 W4 W8 W12 W14 Plan to explore Q2W and Q4W Regimens
Evommune Could Reshape the Future of AD: The Largest I&I Market Expansion of AD Market Outpacing That of Psoriasis © Evommune, Inc. Per Evaluate Pharma (May represent projections and not actual sales); “Year 1” for AD represents 2017 (year of Dupixent launch); “Year 1” for Psoriasis represents 2004 (year of Enbrel launch in plaque psoriasis); 1. Total estimated prevalence in adult and pediatric populations; Estimated per Allergy & Asthma Network, Hanafin & Reed (2007), AAFA, Fuxench et al, (2019); 2. Total estimated prevalence in adult and pediatric populations; Estimated per psoriasis.org, datacenter.aecf.org, Armstrong et al. (2021), Paller et al. (2018), Tannenbaum et al. (2022), Helmick et al. (2014), Rosario-Jansen et al. (2025). Note that slide contains registered trademarks not owned by Evommune 0 5 10 15 20 25 Year After Market Entry of First Advanced Therapy US Sales ($B) Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12 Y13 Y14 Y15 Y16 Y17 Y18 Y19 Y20 Y21 Dupixent (IL-4 / IL-13) Adbry (IL-13) Rinvoq (JAK1) Ebglyss (IL-13) Other Skyrizi (IL-23) Tremfya (IL-23) Stelara (IL-12/IL-23) Cosentyx (IL-17A) Taltz (IL-17A) Bimzelx (IL-17A/IL-17F) Humira (TNFα) Enbrel (TNFα) Remicade (TNFα) Otezla (PDE4) Other Atopic Dermatitis Mod-to-Sev Patients ≈ 13M 1 Where We are Today in the AD Market Psoriasis Growth Driven by Nine Blockbusters Spanning Six MOAs. AD Remains a Concentrated Market with Clear Opportunity for New MOAs and Better Benefit-Risk Ratio. Stelara (IL-12 / IL-23) Bimzelx (IL-17A / IL-17F) Psoriasis Mod-to-Sev Patients ≈ 1.4M 2 Nemluvio (IL-31) Y22
EVO301 Could Command Substantial Market Share in the Potentially $50B+ AD Market as a Clearly Differentiated Biologic © Evommune, Inc. Sales from Evaluate Pharma may represent projections. 1. At maintenance. 2. From ’25-’26. Sales in $M Class Route of Administration1 Launch Year 2025 WW Sales 2025 US Sales Projected Growth2 Projected Peak WW Sales in AD IL-4/-13 Q2W SubQ 2017 12,496 9,234 +9% 17,423 (2030) IL-13 Q2W SubQ 2021 1,508 1,421 +22% 2,469 (2030) IL-13 Q4W SubQ 2024 409 274 +72% 2,625 (2032) IL-31 Q8W SubQ 2024 268 172 +91% 2,759 (2032) Four Marketed AD Biologics Currently ~$15B, Projected to be ~$25B by 2032
Both EBGLYSS and NEMLUVIO, Launched in 2024, Projected for $2.5B+ Global Sales EBGLYSS and NEMLUVIO Outpacing Psoriasis Launches, Highlighting Need for New Options in AD © Evommune, Inc. Sources: IQVIA, based on New to Brand prescriptions. 1 2 3 4 5 6 7 8 9 10 11 12 Months Post-Launch U.S. Monthly TRX (000s) Ebglyss Nemluvio Bimzelx Skyrizi
IL-18BP Evommune Could Reshape the Future of AD: The Largest I&I Market Novel MoAs Enable Treatment Across AD Patient Journey and Severity Spectrum Topical Therapies MRGPRX2 Inhibitors EVO756 and EVO301 Have Synergistic Potential to Address Different Segments of the AD Landscape An AD Patient’s Treatment Journey EVO756 as a first-line oral treatment post topical therapies EVO301 as a preferred biologic for moderate-to-severe patients EVO756 JAK Inhibitors Injection Oral Topical Approved Biologics (IL-4 / IL-13, IL-31) IL-2 / Other EVO301 © Evommune, Inc.
Company Overview © Evommune, Inc.
Luis Peña Founder, President & CEO Eugene Bauer, MD Founder, CMO Kyle Carver, MBA CFO Greg Moss, Esq CBO & CLO Jeegar Patel, PhD CSO Janice Drew, MPH Chief of Development Operations Lou Sehl, PhD SVP, Technical Operations Daniel Burge, MD SVP, Clinical Development Leadership in >25 Companies Key Roles in Almost 30 NDA / BLAs (Acquired by Eli Lilly for $1.1B) (Acquired by Sanofi for $1.9B) (Acquired by GlaxoSmithKline for $2.9B) (Acquired by LEO Pharma for $288M) (Acquired by Bristol Myers Squibb for $13.1B) (Acquired by Eli Lilly for $6.5B) (Acquired by Stiefel for $930M) (Acquired by Angiotech for ~$50M) Proven and Experienced Leadership Team Has Delivered Almost 30 NDAs and BLAs Footnotes: Acquisition prices from press releases Mark Jackson, MD SVP, Clinical Development © Evommune, Inc.
Mid-stage clinical company developing novel therapeutics for immune-mediated chronic inflammatory diseases Two programs in Phase 2: EVO756 (oral MRGPRX2 antagonist) in chronic spontaneous urticaria and atopic dermatitis, with migraine trial planned for mid-2026 EVO301 (long-acting IL-18bp fusion protein) in atopic dermatitis Three clinical data readouts in 2026: EVO301 reported positive data in a Phase 2a in AD (Feb 2026), moving to Phase 2b with subcutaneous formulation EVO756 Phase 2b in CSU expected in June 2026 EVO756 Phase 2b in AD expected in Q3 2026 Proven and experienced leadership team has played key roles in almost 30 NDAs and BLAs Steady cadence of new programs entering the clinic in a broad range of inflammatory diseases © Evommune, Inc. $173 million IPO in Nov 2025 $125 million Private Placement in Feb 2026 ~$307 million of cash & investments as of March 31, 2026 Strong Cash Position with Multiple Clinical Milestones in 2026
Thank You! © Evommune, Inc.